Research shows limited impact of ban on flavored e-cigarettes

Dec.01.2022
Research shows limited impact of ban on flavored e-cigarettes
The US ban on flavored e-cigarettes has had limited effectiveness, as users turn to alternative products and flavors.

On February 6, 2020, the United States Food and Drug Administration banned the sale of several flavors of electronic cigarettes, with some significant exceptions.


According to a survey published in the journal "Tobacco Control," out of 3500 adult users of electronic cigarettes who were surveyed, less than 5% of them stopped using electronic cigarettes due to the ban on flavored e-cigarettes. The remaining respondents switched to other types or flavors of electronic cigarettes or other tobacco products that were not covered by the ban.


More and more literature suggests that the flavorings in e-cigarettes can cause harm when inhaled, making a ban on these flavorings reasonable, according to tobacco research expert and Professor of Public Health Sciences and Community Center Deborah J. Ossip. "But bans don't seem to be effective. People, including young people, can still access flavored products and are still using them," she added. This statement was made at the University of Rochester Medical Center's Department of Public Health and Prevention.


According to Dongmei Li, the lead author of the study and associate professor of clinical and translational research, obstetrics and gynecology, and public health sciences, a significant part of the problem is that the ban does not cover newer products such as disposable e-cigarette pods and e-cigarette pods that use canisters instead of cartridges/boxes.


Other forms of flavored electronic cigarettes, particularly disposable ones, have become very popular after FDA policies were implemented," said Li. "The FDA's policies did not prohibit products with mint or tobacco flavors - our research indicates that many people switched to mint-flavored e-cigarettes after the ban. It seems that many people find menthol to be a favorable taste.


According to this study, nearly 30% of the survey respondents switched to canned or disposable flavored e-cigarettes, and another 30% switched to mint or tobacco flavored pods. Some reported turning to traditional tobacco products: 14% switched to combustible products like cigarettes, and 5% switched to smokeless products such as chewing or dipping tobacco. Less than 5% of respondents stopped using e-cigarettes after the FDA ban.


Researchers used statistical models to identify factors related to changes in e-cigarette usage behavior. They found a close correlation between using tank system e-cigarettes and switching to other flavors not regulated by the FDA's flavor law enforcement policies.


The use of mint-flavored electronic cigarettes over the past 30 days is associated with switching to mint-flavored electronic cigarettes. Those who reported smoking every day or every few days were more likely to switch to tobacco-flavored electronic cigarettes or combustible tobacco products.


On the other hand, people who use flavored electronic cigarettes without nicotine are more likely to quit smoking. Although the study was not intended to establish a causal relationship, the association supports previous research showing that reducing nicotine levels in cigarettes can help smokers quit. However, further research is needed to better understand the relationship between the use of low-nicotine electronic cigarettes and smoking cessation.


Looking towards the future, Li Dongmei believes that if this policy covers all flavors of electronic cigarettes (including mint and all types of electronic cigarettes) and actively monitors the implementation and compliance of the policy, then the policy may be effective. "Both are important in reducing the popularity of electronic cigarettes among young people in the United States," she said.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canada Health Minister Says She Is Not Considering Looser Nicotine Pouch Retail Rules as PMI-Linked Group Pushes for Wider Access
Canadian Health Minister Marjorie Michel says she is not considering loosening retail restrictions on nicotine pouches. Canada regulates pouches containing 4 mg or less of nicotine per unit as non-prescription nicotine replacement therapy and requires newer NRT formats such as pouches to be sold from behind pharmacy counters. Meanwhile, Unsmoke Canada, linked to Philip Morris International's Canadian business, is pushing to allow pouches in convenience stores and other general retail outlets. Health Canada also acknowledges continued unauthorized sales, while recent research shows rising pouch use among Canadian youth aged 16 to 19.
Sep.24
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
Product | JNR Launches Shisha Hookah 70K E-Hookah With 60ml E-Liquid and 0.6% Nicotine
JNR has introduced the Shisha Hookah 70K, a high-capacity rechargeable disposable vape designed around a hookah-inspired experience. The device comes prefilled with 60ml of e-liquid at 6mg/ml (0.6%) nicotine strength, alongside a 1,000mAh rechargeable battery and a 0.38Ω single mesh coil. It also features adjustable airflow and battery and e-liquid level displays. JNR claims the device can deliver up to 70,000 puffs and offers more than 20 flavors. Retail listings for the product have appeared in markets including Tunisia.
Market
Aug.24 by 2Firsts Perspectives
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14